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Abstract
Objective To identify historical and clinical findings at emergency
department presentation associated with severe H1N1 outcome in
children presenting with influenza-like illness.
Design Multicentre retrospective case-control study.
Setting 79 emergency departments of hospitals associated with the
Pediatric Emergency Research Networks in 12 countries.
Participants 265 children (<16 years), presenting between 16 April and
31 December 2009, who fulfilled Centers for Disease Control and
Prevention criteria for influenza-like illness and developed severe
outcomes from laboratory confirmed H1N1 infection. For each case, two
controls presenting with influenza-like illness but without severe outcomes
were included: one random control and one age matched control.
Main outcomemeasuresSevere outcomes included death or admission
to intensive care for assisted ventilation, inotropic support, or both.
Multivariable conditional logistic regression was used to compare cases
and controls, with effect sizes measured as adjusted odds ratios.
Results 151 (57%) of the 265 cases were male, the median age was 6
(interquartile range 2.3-10.0) years, and 27 (10%) died. Six factors were
associated with severe outcomes in children presenting with influenza-like
illness: history of chronic lung disease (odds ratio 10.3, 95% confidence
interval 1.5 to 69.8), history of cerebral palsy/developmental delay (10.2,
2.0 to 51.4), signs of chest retractions (9.6, 3.2 to 29.0), signs of
dehydration (8.8, 1.6 to 49.3), requirement for oxygen (5.8, 2.0 to 16.2),
and tachycardia relative to age).
Conclusion These independent risk factors may alert clinicians to
children at risk of severe outcomes when presenting with influenza-like
illness during future pandemics.
Introduction
In June 2009 the World Health Organization declared the first
global influenza pandemic in 41 years.1 From early in the
pandemic, children—particularly those aged under 5
years2—were considered a population at higher risk of morbidity
and mortality from pandemic H1N1 (pH1N1) infection.1
Several studies from around the world have included children
and adults admitted to hospital or intensive care units with
pH1N1 infection.3-18 However, these data vary in format and
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emphasis, making direct comparison between studies difficult.
Furthermore, data on severe outcomes (including death) and
risk factors for severe outcomes are limited. One large
multi-country analysis identified that risk for severe outcomes
was associated with eight pre-existing medical conditions;
unfortunately, data for paediatric and adult patients were
combined, making conclusions specific to children difficult to
formulate.19
During the pandemic, emergency departments and primary care
facilities experienced large surges of children presenting with
influenza-like illness.20-22 These surges corresponded to influxes
of pH1N1 related admissions to intensive care units. To date,
no reports have detailed which factors in children with
influenza-like illness and pH1N1 infection at presentation to
emergency departments are associated with a risk of progression
to severe disease or death. Such information would be highly
relevant for informing emergency department and primary care
clinicians regarding risk stratification, resource allocation, and
clinical disposition in future pandemics.
We did this study to identify historical and clinical findings at
presentation to emergency departments associated with severe
outcomes of pH1N1 infection in children presenting with
influenza-like illness. To answer this question on a global scale,
we studied children presenting to the emergency departments
of hospitals associated with the Pediatric Emergency Research
Networks (PERN).23 PERN comprises representative hospitals
from the five major paediatric emergency medicine research
networks located in Europe, the Middle East, North America,
and Australasia. Together, the five research networks have
access to data from more than three million paediatric
emergency department presentations annually, from more than
100 hospitals, in four of the six WHO regions.
Methods
We did a retrospective case-control study of children (<16 years)
who presented with influenza-like illness to 79 emergency
departments in 12 countries between 16 April and 31 December
2009, during the 2009 H1N1 pandemic.
Participants
Cases—Cases were children who fulfilled the Centers for
Disease Control and Prevention (CDC) criteria for influenza-like
illness at emergency department presentation (fever measured
at home or hospital (temperature ≥37.8°C or ≥100°F) and either
cough or sore throat),22who subsequently died or were admitted
to an intensive care unit for assisted ventilation,
inotropic/vasopressor support, or both (defined as severe
outcomes) as a result of laboratory confirmed pH1N1 infection.
Laboratory confirmation was either by polymerase chain
reaction or viral culture. We excluded patients as cases if they
were admitted directly into an intensive care unit from a hospital
that was not a study site (because emergency department
documentation and controls were not available), did not fulfil
CDC criteria for influenza-like illness in the emergency
department, or had suspected pH1N1 infection that was not
confirmed by laboratory testing, as defined above.
Controls—For each case, we identified two controls who
presented with influenza-like illness to the same emergency
department but who did not develop severe outcomes: one
random control and one age matched control. The random
control was the patient presenting most proximately before the
case who fulfilled the CDC criteria for influenza-like illness.
The age matched control was the patient presenting most
proximately after the case who fulfilled the CDC criteria for
influenza-like illness and who was in the same age group as the
case (<2 years, 2 to <5 years, 5 to <10 years, 10 to 15 years).
Patients were eligible as controls independently of hospital
admission or laboratory testing for pH1N1 infection.
Severe H1N1 without influenza-like illness in emergency
department (WILIE) group—The study also included children
with laboratory confirmed pH1N1 infection with severe
outcomes as defined above, but who do not meet the CDC
criteria for influenza-like illness in the emergency department.
We included this additional group of patients only if they had
presented to a study site’s emergency department.We identified
these patients to assess accurately the proportion of severely
affected patients with pH1N1 infection who present to
emergency departments without influenza-like illness and to
document treatment and outcome data for all patients with severe
pH1N1 infection. We did not include this group in the primary
case-control analysis.
We identified potential cases, controls, and WILIE patients at
individual hospitals by a combination of searching intensive
care unit, emergency department, laboratory, and mortality
databases. Confirmation of inclusion in the study was
determined by detailed review of patient medical records.
Data collection
We collected data for all patient groups according to standard
methods for retrospective chart reviews.24 Site investigators (all
physicians) used a detailed manual of operations with all
variables defined a priori. Variables were defined according to
pre-specified standard international definitions. A data source
hierarchy was pre-specified for all data points. Data included
premorbid history, patient’s history at clinical presentation,
physical examination, laboratory/radiographic investigations,
management, and outcome. For reasons of feasibility, site
investigators were not masked to outcome or case/control status.
We used the Pediatric Risk of Admission Score, second
generation (PRISA II), to measure severity of illness at
emergency department presentation.25
Analysis
We evaluated the univariable association of clinical risk factors
with severe outcomes both between the cases and the random
controls and between the cases and the age matched controls.
We did conditional logistic regression analyses allowing for
matching by site for the cases and the random controls and
allowing for matching by site and age for the cases and the age
matched controls. We did these analyses to determine possible
variables for inclusion in multivariable models, as well as to
delineate better the effect of age. For the 11% of cases with
multiple emergency department visits, we used variables from
the first recorded visit. We created multivariable models by
using the same conditional logistic regression analyses. We
created models by using a two step process to maximise sample
size and power while restricting variables included at each stage
of the analysis. Variables significant at the P=0.1 level in the
univariable analysis, and with a prevalence among cases and
controls of more than 2%, were included in the initial
multivariable models. We created three initial models by using
a backward stepwise approach (that is, removal of
non-significant (P>0.05) variables in a stepwise manner) of
comorbidity (for the random control model, six variables
reduced to four), historical symptoms (11 variables reduced to
five), and physical examination variables (seven variables
reduced to three).We then further reduced the resulting variables
(12) by a backward stepwise approach in a final combined
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model. We used imputation to account for missing variables in
the multivariable models. We included the continuous variables
of heart rate and respiratory rate in the multivariable models as
continuous variables by using cubic and quadratic terms,
respectively, to maximise power, and according to the relation
shown in modelling, by using generalised additive models at
the univariable level. As both variables vary with age across
the paediatric age spectrum, age was forced into the models
using these variables. Oxygen saturations were dichotomised
in the multivariable models to reflect clinical practice and
biological plausibility.
We repeated themultivariable modelling in a sensitivity analysis
without imputation and with heart rate and respiratory rate as
dichotomised variables with clinically accepted thresholds, to
assess the robustness of the imputation process and to generate
more clinically meaningful odds ratios rather than odds ratios
per change in unit from the modelling.We did further sensitivity
analysis using bootstrap resampling techniques, with 1000
iterations, of the univariable analysis and of the multivariable
models at all steps, to explore over-optimism of the variable
selection processes used. We report effects for risk factors as
adjusted odds ratios with 95% confidence intervals for
dichotomised variables and as parameter estimates with 95%
confidence intervals for continuous quadratic and cubic
variables. We calculated the C statistics for all resulting models.
We did additional analyses of cases and the WILIE patients to
compare emergency department management, subsequent
management, and outcome among all patients with severe
outcomes, regardless of influenza-like illness status, who either
died or survived. We used SAS, version 9.1, software for all
analyses.
Results
We identified 265 cases at 79 sites, as well as 56 additional
children who fulfilled criteria for severe outcomes associated
with pH1N1 but who did not have influenza-like illness at
presentation (WILIE group). Boys constituted 151 (57%) cases,
with a similar proportion in the two control groups (table 1⇓).
The mean age of the cases was 6.6 (SD 4.7) years; the age
matched controls were of a similar age, and the random controls
were an average 14 months younger. Cases were more likely
to look unwell at presentation, with PRISA-II scores suggesting
a need for admission to intensive care (median 19, interquartile
range 14-29). No significant differences existed between cases
and controls in duration of symptoms of influenza-like illness
or maximum temperature recorded at home. A history of cough
was present in more than 90% of cases and controls. A history
of a sore throat was more prevalent in both control groups
compared with cases (table 1⇓).
Predictor variable data availability
Data were available for each predictor variable in at least 90%
of cases and controls. Exceptions included questions concerning
whether the patient had seen a physician for the presenting
illness (available for 86% of age matched controls), prolonged
capillary refill time (available for 69-74% in all groups), and
auscultatory findings and dehydration status (available for 89%
and 81% of cases, respectively) (tables 2⇓ and 3⇓).
Univariable analysis
The results of the two univariable analyses comparing the cases
with the random controls and the age matched controls were
similar. We recorded 193 (73%) cases with pre-existing
comorbidities (comparison with random controls: odds ratio
4.2, 95% confidence interval 2.8 to 6.4; comparison with age
matched controls: 6.8, 4.1 to 11.1). Specifically, asthma, chronic
lung disease, heart disease, preterm birth, and cerebral
palsy/developmental delay were all significantly associated with
case status. Furthermore, chronic renal disease (n=8, 3%) was
present almost exclusively in cases. Diabetes, pregnancy, and
immune suppression/malignancy occurred infrequently in both
cases and controls (table 2⇓).
At emergency department presentation, a history of dyspnoea,
increased/purulent sputum, irritability, and wheezing were all
significantly more common in cases than in controls, whereas
diarrhoea, nausea/vomiting, generalised weakness,
syncope/dizziness, myalgia, and chest pain were not. A history
of seizures (n=28, 11%) and apnoea (n=10, 4%) occurred almost
exclusively in cases. Headache and rhinorrhoea occurred
significantly less commonly in the cases compared with both
control groups. Cases were also more likely to have been
previously seen by a physician for the current illness and
prescribed either antivirals (exclusively oseltamivir) or
antibiotics (table 2⇓). On physical examination in the emergency
department, all signs investigated, except temperature above
38.9°C, were associated with case status (table 3⇓).
As expected, given the higher clinical severity,
laboratory/radiographic investigations within four hours of
arrival in the emergency department were conducted more
frequently in cases than in controls; 218 (82%) of cases had
chest radiography and 226 (85%) had basic laboratory
investigations. In comparison, only 74 (28%) of random controls
and 69 (26%) of age matched controls had chest radiography,
and 45 (17%) of random controls and 44 (17%) of age matched
controls had basic laboratory investigations (P<0.001 for all
comparisons). In those who had laboratory and radiographic
investigations within four hours of arrival in the emergency
department, lobar pneumonias and platelet counts below 150
000/μL were associated with case status, whereas non-lobar
pneumonias, haemoglobin concentrations below 10 g/dL,
leukocyte counts above 15 000/μL, neutrophil counts above 10
000/μL, blood urea nitrogen above 20mg/dL, and serum glucose
above 200 mg/dL were not. Acidosis (pH<7.3) was exclusively
present in cases, although blood pHwas reported for only a few
controls (table 3⇓).
Multivariable models
We did not include variables from laboratory and radiographic
investigations in the multivariable analysis owing to the low
prevalence of these variables in the control groups. The
multivariable analysis using the random and the age matched
controls resulted in the same six variable model that included
history of chronic lung disease, history of cerebral
palsy/developmental delay, requirement for oxygen or low
oxygen saturations, tachycardia relative to age, presence of chest
retractions, and signs of dehydration (C statistic for model using
random controls 0.925; C statistic for model using age matched
controls 0.905) (tables 2⇓ and 3⇓). Additionally, symptoms of
breathlessness, irritability/drowsiness, and increased/purulent
sputumwere significant at the P<0.1 level in the random control
model, and symptoms of irritability/drowsiness were significant
at the P<0.1 level in the age matched control model
(supplementary table A). In the bootstrap analysis, we identified
the same possible predictor variables at all stages of the
modelling process. Sensitivity analyses, without imputation and
with heart rate and respiratory rate as dichotomised variables,
using the random controls resulted in a seven variable model
(removal of presence of dehydration and addition of symptoms
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of breathlessness and irritability/drowsiness), and those using
the age matched controls resulted in a three variable model
(removal of a history of chronic lung disease, tachycardia
relative to age, and signs of dehydration) (supplementary table
B).
Outcome for cases and the WILIE group
Of the 321 paediatric patients with severe pH1N1 outcome
identified, 265 (83%) fulfilled the Centers for Disease Control
and Prevention criteria for influenza-like illness at emergency
department presentation (cases). The additional 56 patients in
the WILIE group had similar demographics and comorbidities
to cases. However, more children in the WILIE group had
immune suppression/malignancy (n=4, 7%; influenza-like illness
cases n=5, 2%; odds ratio 4.0, 1.0 to 5.4).
Within four hours of arrival at the emergency department, 63%
of both cases andWILIE patients received antibiotic treatment,
40% received antiviral treatment, 64% received intravenous
fluid boluses, 42% had ventilatory support started/continued,
and 14% had inotropic support started. Two hundred and eighty
six (89%) patients were admitted to hospital at the time of their
first emergency department presentation.Most admitted patients
subsequently received antibiotic and antiviral treatment.
Approximately one half of the children received systemic
corticosteroid treatment, and a small number received
immunoglobulin treatment. The most common complications
during hospital admissions were secondary pneumonias,
secondary bacteraemias, and acute respiratory distress syndrome
(table 4⇓).
Mortality
Among the 321 patients with severe pH1N1, 34 (11%) deaths
occurred (27 (10%) deaths among cases and 7 (13%) among
WILIE patients). Two patients arrived dead at the emergency
department. The other 32 who subsequently died were less likely
to have received antiviral treatment within the first four hours
of initial emergency department presentation than were those
who survived (P=0.02). Those who died received greater
inotropic and ventilatory support and developed more frequent
complications (table 5⇓). Of the seven variables identified in
the multivariable analyses, only cerebral palsy/developmental
delay was associated with an increased risk of death (odds ratio
2.6, 1.2 to 5.5).
Discussion
We identified 321 children with severe outcomes due to pH1N1
infection at 79 sites in 12 countries, from a global consortium
of paediatric emergency medicine networks during the first
season of the H1N1 pandemic. Of these, 265 (83%) presented
to emergency departments with Centers for Disease Control and
Prevention defined symptoms of influenza-like illness and were
matched with random and age matched controls with
influenza-like illness who did not have severe outcomes. We
identified six factors that were associated with severe outcomes
in children presenting to emergency departments with
influenza-like illness, including two chronic disease factors
(chronic lung disease and cerebral palsy/developmental delay)
and four physiological/physical examination factors
(requirement for oxygen or low oxygen saturations, tachycardia
relative to age, presence of chest retractions, and signs of
dehydration).
Comparison with other studies
In this large study, we compared comorbidities as well as clinical
findings at presentation between children with and without
severe outcomes who presented with influenza-like illness
during a global pandemic. This analysis directly relates to the
primary concern of the clinician who is caring for a child with
an influenza-like illness in the middle of an epidemic: is this
patient at risk of severe outcomes? One previous analysis
detailed the risk of eight comorbidities in an aggregate dataset
of 9700 children and adults with pH1N1 admitted to intensive
care units in 19 countries.19 However, the study was limited by
missing data, as only eight of the 19 countries provided full data
on all eight risk factors. Furthermore, owing to lack of individual
patient level data, meta-regression was not considered robust
and the independent contribution of individual risk factors to
outcome could not be determined. Risk was not provided for
paediatric patients alone, and data were not provided on
symptoms at presentation nor on physical examination or
laboratory/radiographic findings. Nevertheless, the results
support our finding of an increased risk of severe outcome
among patients with one or more comorbidities,19 as do several
smaller, single country paediatric studies.3 6 7 9 10
Several smaller studies have described paediatric patients
admitted to intensive care units by city (Denver, n=80) state
(California, n=96), and country (Australia and New Zealand,
n=83; Argentina, n=147).3-15 However, these studies typically
described demographic data and comorbidities and did not focus
on clinical predictors of severity.5-8 Intensive care unit cohorts
fromCalifornia andDenver were comparedwith pH1N1 hospital
admissions to non-intensive care. Multivariable regression of
the California data indicated that congenital heart disease and
cerebral palsy/developmental delay were associated with severe
outcome, whereas Hispanic ethnicity and black race were not.7
Similar analysis of the Denver data indicated that older age,
pre-existing neurological conditions (including cerebral
palsy/developmental delay), hypoxia on admission, and altered
mental status were all associated with severe outcome.6Cerebral
palsy/developmental delay was significant in both of these
previous cohorts, as it was in our random and age matched
analyses. Such patients are considered to be at increased risk of
respiratory infections owing to their inability to handle
respiratory secretions as well as other factors, including
under-nutrition.26
Although all nine respiratory variables we report were found to
be significantly associated with severe outcomes in our
univariable analyses, chest retractions and hypoxia were the
only respiratory variables present in both our random and age
matched models. This suggests that these two respiratory
variables are the strongest respiratory predictors of severe
pH1N1 outcome. As diffuse alveolar damage, tracheitis, and
necrotising bronchiolitis are consistent histopathological findings
in fatal cases of pH1N1,1 that physical signs of dyspnoea and
hypoxia are such important predictive factor is not surprising.
In our study, not surprisingly, laboratory and radiographic
investigations were done more often in cases than in controls.
The clinician’s assessment of disease severity probably greatly
affected this, with patients who looked most unwell incurring
more investigations. Although these investigations were not
included in the multivariable analyses, on univariable analysis
these investigations, with the exception of chest radiography,
seem to have limited predictive value for severe outcomes from
pH1N1 infection for children presenting with influenza-like
illness.
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A recent meta-analysis of the efficacy of oseltamivir in treating
influenza infections emphasised the lack of data on its efficacy
in preventing severe outcomes in pH1N1 infection and in
influenza infections in general.27 In our study, we were able to
show an association between oseltamivir treatment started in
the emergency department and a reduced frequency of death in
children subsequently admitted to an intensive care unit for
assisted ventilation, inotropic/vasopressor support, or both.
However, this result was confounded by the fact that patients
who ultimately died presented to the emergency department
later in the course of their illness than did those who survived,
and perhaps it was this late presentation rather than the
oseltamivir treatment itself that affected mortality. Overall, and
consistent with other pH1N1 studies,28-31 we confirmed that
oseltamivir started within the first two days of symptoms is
associated with decreased mortality. Although this evidence is
not from randomised trials, it does support the timely use of
oseltamivir in patients at risk of severe outcomes.
Limitations and strengths of study
Our study has several limitations owing to its retrospective
design, including the risk of ascertainment, confirmation, and
selection biases, as well as missing data. To minimise these
limitations, senior physicians abstracted data at each site by
following explicit instructions for data abstraction in a detailed
manual of operations. In addition, data entry was facilitated by
electronic forms with electronically configured logic checks.
The use of two controls for each case limited both the risk of
selection bias and the effect of missing data. The effect of
missing data was further minimised by the use of imputation.
The study was conducted predominately in academic centres,
and this may raise concerns about generalisability to other
settings. To overcome this, we excluded patients who were
transferred from other emergency departments to our intensive
care units, thus limiting cases and controls to “walk-ins” and
referrals who were not already deemed critically ill.
Furthermore, we included cases from 79 emergency departments
in 12 countries, with a wide range of number of annual paediatric
visits (5000 to >100 000 per year), in departments that are both
paediatric emergency departments and mixed paediatric/adult
emergency departments and are located in both secondary and
tertiary hospitals.
Controls were included in the study irrespective of pH1N1 status
and defined by influenza-like illness criteria alone. Therefore,
control patients probably included patients with other viral
infections as well as those with pH1N1 infection. The exact
proportion of influenza-like illness presentations that tested
positive for pH1N1 varied considerably between locations in
the pandemic, although during the pandemic the prevalence of
pH1N1 mirrored the prevalence of influenza-like illness.5 At
any given site participating in this study, prevalence of pH1N1
among children presenting with influenza-like illness would
have also varied temporally. However, the comparison of
children with pH1N1 infections who had severe outcomes
(cases) with influenza-like illness controls provides critical
information to front line clinicians managing surges of children
presenting with influenza-like illness during a pandemic.
Recognition of children who will develop severe outcomes is
difficult. A considerable proportion of paediatric presentations
to emergency departments are with fever and tachycardia. In
addition, febrile infants with influenza-like illness are often
crying and inconsolable and are reported by their parents as
being lethargic or irritable. Most children who present in this
fashion have benign outcomes and disease course.32 Thus, our
highly clinically relevant comparison is one of the key strengths
of the study, as we have provided clinicians with meaningful
information to differentiate those febrile children with
influenza-like illness who are at greater risk of developing severe
outcomes from those who are not. In contrast, studies comparing
severe pH1N1 cases with non-severe pH1N1 controls have
considerable selection bias and are of less clinical relevance, as
rapid, inexpensive, reliable screening tests for pH1N1 are not
available. The inclusion of patients with severe H1N1 without
influenza-like illness in emergency departments (WILIE
patients) in the study also provides reassurance that 83% of
children destined to have severe pH1N1 present with symptoms
of influenza-like illness.
Our final multivariable models included only predictors present
in more than 2% of cases and controls to guarantee the
robustness and stability of the final models. Parameter estimates
for multivariable modelling are often not stable when presence
of a variable occurs infrequently. Thus, some clinically
important predictors may have been excluded from our models.
For example, both history of apnoea and presenting already
intubated occurred exclusively in 10 (4%) cases. Similarly,
history of renal disease (eight cases, 3%), presentation after
seizure (28 cases, 11%), presence of prolonged capillary refill
time or shock (51/183 cases, 28%), and presence of altered
mental status (63/239 cases, 26%) were almost exclusively
present in cases. These variables remain potentially (and
plausibly) important predictors of severe outcome and should
not be overlooked by clinicians. We found very low prevalence
of pregnancy, diabetes, and malignancy/immunosuppression
among both cases and controls, so the findings of our study
must be interpreted with caution in these patients.
The multivariable models for the random and age matched
controls share the same six predictors, indicating the robustness
and stability of both our selection and modelling processes.
Symptoms of breathlessness, irritability/drowsiness, and
increased/purulent sputum were significant at the P<0.1 level
in the modelling and should not be overlooked by clinicians.
Five of the six predictors identified in the modelling process
were also present in sensitivity analysis using non-imputed data
and dichotomised respiration rate and heart rate variables, again
supporting the final model. Signs of dehydration, the only
predictor not present in the sensitivity models, was removed
during the modelling process owing to lack of stability
secondary to missing data and few controls with dehydration.
The study was not adequately powered to assess whether
prognostic effects are consistent across sites and countries. This
is likely, however, as all study sites were recognised emergency
departments, all are part of established paediatric research
networks, and predictor variables collected were all objective
standard paediatric variables, supported by a priori standard
international definitions.
Our study has several additional strengths. Our data are
particularly robust owing to the precise definition of severe
outcomes including ventilatory or inotropic support, in addition
to death. This strict and objective outcome definition allows for
increased confidence when comparing patients across centres;
using intensive care unit admission alone as an outcome
definition is subject to variability of thresholds for admission
to intensive care between study sites. In other case series,
ventilatory support of children with pH1N1 infection admitted
to intensive care units has varied considerably from 30% to
100%.8 33 Similarly, mortality has also varied substantially
(7-39%).5 8 However, those cohorts with higher mortality were
more ill at intensive care unit admission, confirming that
admission to intensive care units is subject to considerable
variance and should not be used alone for global comparisons
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of disease severity. Our precise definition for severe outcomes
also captured patients with a terminal comorbidity who may
have been denied intensive care unit support, by including deaths
irrespective of intensive care units admission. Furthermore, as
intensive care unit, emergency department, laboratory, and
mortality databases were searched for cases at sites, our search
strategy would be unlikely to have missed a large number of
cases. That our study found very similar case rates to regional
reports provides further reassurance.5 Finally, although our study
did not include any sites from low income countries where most
childhood respiratory mortality occurs, our results are
particularly generalisable to high income countries, as we
included data from 79 sites in 12 countries in four of the six
WHO regions.
Conclusion
Our study has identified robust, generalisable, and independent
risk factors that may alert clinicians to children at risk of severe
outcomes when presenting with influenza-like illness during a
pandemic. Independent risk factors for severe outcomes included
findings from premorbid history (chronic lung disease, cerebral
palsy/developmental delay) and physiology/physical
examination (requirement for oxygen, tachycardia relative to
age, presence of chest retractions, signs of dehydration).
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What is already known on this topic
During the 2009 H1N1 pandemic, paediatric emergency departments worldwide experienced a surge in total volume of patients owing
to children presenting with influenza-like illness
Risk factors for subsequent severe outcome in such children were not known
What this study adds
This global study identified six independent risk factors for severe outcomes in children presenting with influenza-like illness during the
2009 H1N1 pandemic
These factors were history of chronic lung disease and cerebral palsy/developmental delay, signs of chest retractions, tachycardia for
age, requirement for oxygen, and signs of dehydration
These risk factors may alert clinicians to children at risk of severe outcomes when presenting with influenza-like illness during future
pandemics
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Tables
Table 1| Age, severity at emergency department presentation, and Centers for Disease Control and Prevention influenza-like illness
characteristics of children in all study groups. Values are numbers (percentages) unless stated otherwise
Age matched controls (n=265)Random controls (n=265)Cases (n=265)Characteristics
6.4 (4.5)5.4 (4.2)*6.6 (4.7)Mean (SD) age (years)
143 (54)137 (52)151 (57)Male sex
5 (0-5)*5 (3-6)*19 (14-29)Median (interquartile range) PRISA-II score
39.0 (0.8)39.2 (0.8)39.0 (0.7)Mean (SD) maximum fever recorded at home (°C)
2 (1-3)2 (1-3)2 (1-3)Median (interquartile range) fever duration (days)
245 (93)*255 (96)259 (98)Cough on history
2 (1-3)2 (1-3)2 (1-3)Median (interquartile range) cough duration (days)
88 (33)*81 (31)*46 (17)Sore throat on history
2 (1-3)2 (1-3)2 (1-3)Median (interquartile range) sore throat duration (days)
PRISA-II=Pediatric Risk of Admission Score (second generation).25
*P<0.05 compared with cases.
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Table 2| Comparison of factors from comorbidities and history of current illness associated with development of severe outcomes from
pH1N1 infection between cases and control study groups
Age matched controls (n=265)Random controls (n=265)
Cases
(n=265)—No
(%)Predictor
Odds ratio (95% CI)*
No (%)
Odds ratio (95% CI)*
No (%)
Multivariable
modelUnivariable analysis
Multivariable
model
Univariable
analysis
†1.1 (0.8 to 1.6)143 (54)†1.2 (0.9 to 1.7)137 (52)151 (57)Male sex
Comorbidities
‡2.7 (1.7 to 4.2)48 (18)‡1.7 (1.1 to 2.5)66 (25)94 (36)Asthma
¶§0 (0)¶§0 (0)1 (0)Pregnancy
8.5 (1.6 to
45.1)
9.8 (4.2 to 22.8)7 (3)10.3 (1.5 to
69.8)
14.5 (5.3 to 39.9)4 (2)50 (19)Chronic lung disease
‡6.0 (2.3 to 15.5)5 (2)†3.3 (1.6 to 7.0)9 (3)30 (11)Heart disease
¶1.5 (0.3 to 9.0)2 (1)¶§0 (0)3 (1)Diabetes
¶8.0 (1.0 to 64.0)1 (0)¶§0 (0)8 (3)Renal disease
¶1.3 (0.3 to 4.7)4 (2)¶1.7 (0.4 to 7.0)3 (1)5 (2)Malignancy/immunosuppression
65.9 (8.6 to
506)
34.5 (8.5 to 141)5 (2)10.2 (2.0 to
51.4)
14.0 (5.7 to 34.7)7 (3)72 (27)Cerebral palsy/developmental
delay
†4.1 (2.0 to 8.5)14 (5)†3.5 (1.8 to 6.9)14 (5)42 (16)Preterm birth
Current illness
‡9.9 (5.7 to 17.1)31 (12)‡11.0 (6.1 to 19.9)35 (13)155 (58)Dyspnoea
¶§0 (0)¶§0 (0)10 (4)Apnoea
†0.3 (0.2 to 0.6)46 (17)†0.4 (0.2 to 0.7)40 (15)19 (7)Headache
†1.2 (0.9 to 1.7)86 (33)†1.2 (0.8 to 1.7)89 (34)98 (37)Nausea/vomiting
†1.0 (0.6 to 1.6)35 (13)†1.3 (0.8 to 2.3)27 (10)35 (13)Diarrhoea
‡11.0 (3.4 to 35.9)5 (2)‡11.3 (3.5 to 36.9)4 (2)35 (13)Increased/purulent sputum
†5.6 (2.2 to 14.5)5 (2)¶28.0 (3.8 to 206)1 (0)28 (11)Seizures
†1.6 (0.8 to 3.1)18 (7)‡2.3 (1.0 to 5.9)16 (6)27 (10)Generalised weakness
†0.6 (0.2 to 1.7)9 (3)†1.0 (0.3 to 4.0)5 (2)5 (2)Dizziness
‡2.9 (1.7 to 5.1)22 (8)‡2.6 (1.6 to 4.5)24 (9)55 (21)Irritable/drowsy
¶0.7 (0.1 to 4.0)3 (1)¶§0 (0)2 (1)Collapse/syncope/dizziness
†7.0 (3.5 to 14.1)15 (6)†2.8 (1.7 to 4.6)31 (12)69 (26)Wheezing
†0.6 (0.3 to 1.2)27 (10)†0.4 (0.2 to 0.8)38 (14)18 (7)Myalgia
†2.3 (0.9 to 5.6)9 (3)†1.4 (0.7 to 2.8)13 (5)18 (7)Chest pain
‡0.5 (0.3 to 0.7)126 (48)‡0.4 (0.3 to 0.7)130 (49)87 (33)Rhinorrhoea
†2.2 (1.4 to 3.2)81/227 (36)†2.5 (1.7 to 3.9)79/240 (33)134/251 (53)Previously seen physician
†2.9 (1.3 to 6.4)8/260 (3)†2.3 (1.1 to 5.1)11/254 (4)23/254 (9)Antiviral treatment started
†2.2 (1.4 to 3.6)34/256 (13)†2.1 (1.3 to 3.4)35/249 (14)66/250 (26)Antibiotics started
*Random control results adjusted for site, and age matched control results adjusted for site and age, using conditional logistic regression.
†Not identified as significant in univariable analyses or in initial multivariable models.
‡Not identified as significant in final model.
§Estimate and CI not calculated owing to non-prevalence in controls.
¶Not included in modelling process owing to prevalence in cases or controls ≤2%.
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Table 3| Comparison of factors from physical examination and laboratory and radiographic investigations, associated with development
of severe outcomes from pH1N1 infection between cases and control study groups
Age matched controls (n=265)Random controls (n=265)
Cases
(n=265)—No
(%)Predictor
Odds ratio (95% CI)*
No (%)
Odds ratio (95% CI)*
No (%)
Multivariable
model
Univariable
analysis
Multivariable
model
Univariable
analysis
Physical examination
¶§0 (0)¶§0/261 (0)10/261(4)Intubated on arrival
†0.8 (0.5 to 1.2)73 (28)†0.9 (0.6 to 1.4)66 (25)62 (23)Fever >38.9°C
†0.15 (0.046 to 0.26)—†0.11 (-0.0036 to
0.22)
——Respiratory rate*
(linear)
†−0.00057 (−0.0019
to 0.00079)
—†−0.00026 (−0.0017
to 0.0011)
——Respiratory rate*
(quadratic)
−0.085 (−0.16
to −0.0079)
−0.19 (-0.30 to
−0.086)
—0.72 (0.0074 to
1.44)
−0.35 (−0.72 to
0.028)
——Heart rate* (linear)**
0.00041
(0.00009 to
0.00072)
0.0019 (0.00093 to
0.0029)
—−0.0055
(−0.011 to
−0.0003)
0.0029 (0.00017 to
0.0055)
——Heart rate*
(quadratic)**
—-0.000005
(−0.000007 to
−0.000002)
—0.000013
(0.0000006 to
0.000025)
−0.000007
(−0.000013 to
−0.0000008)
——Heart rate* (cubic)**
12.9 (3.8 to
44.2)
39.7 (12.6 to 125)16/216 (7)5.8 (2.0 to
16.2)
19.8 (8.7 to 45.0)13/220 (6)151/247 (61)On oxygen or
saturation <93%
12.9 (4.2 to
38.9)
18.5 (9.0 to 38.0)20/248 (8)9.6 (3.2 to
29.0)
20.1 (9.6 to 42.3)22/250 (9)149/240 (62)Chest retractions
‡25.2 (10.7 to 59.7)11/241 (5)†17.2 (8.2 to 36.1)15/244 (6)120/222 (54)Accessory muscle
use
†7.8 (4.1 to 14.8)18/250 (7)†7.2 (3.8 to 13.5)24/252 (10)85/236 (36)Crepitations/rales
†8.1 (4.6 to 14.4)28/254 (11)†7.6 (4.4 to 13.2)31/259 (12)120/248 (48)Wheeze/rhonchi
¶16.7 (5.2 to 53.4)4/196 (2)¶25.0 (6.1 to 103)3/189 (2)51/183 (28)Prolonged
CRT/shocked
¶76.3 (10.3 to 564)2/254 (1)¶77.8 (10.5 to 578)2/255 (1)63/239 (26)Altered mental status
10.7 (2.0 to
57.8)
12.3 (4.5 to 33.6)7/246 (3)8.8 (1.6 to
49.3)
14.3 (4.9 to 42.1)5/244 (2)43/214 (20)Signs of dehydration
Laboratory and radiographic investigations
††6.2 (3.1 to 12.5)11/69 (16)††5.1 (2.7 to 9.6)14/74 (19)118/218 (54)Abnormal chest
radiograph
††6.0 (1.8 to 20.4)10/67 (15)††5.0 (1.7 to 14.6)13/73 (18)100/211 (47)Lobar pneumonia
††5.7 (1.3 to 24.5)2/67 (3)††1.7 (0.4 to 7.0)6/69 (9)29/195 (15)Bronchopneumonia
††1.2 (0.4 to 3.6)4/39 (10)††1.2 (0.4 to 3.7)4/40 (10)24/203 (12)Haemoglobin <10
g/dL
††2.0 (0.7 to 6.1)4/40 (10)††0.6 (0.3 to 1.2)12/42 (29)38/206 (18)Total leukocyte count
>15 000/μL
††1.2 (0.5 to 2.5)11/32 (34)††2.0 (0.9 to 4.3)9/41 (22)70/197 (36)Neutrophil count >10
000/μL
††§0/6 (0)††§0/3 (0)47/147 (32)pH <7.3
††0.9 (0.4 to 2.3)8/22 (36)††1.1 (0.4 to 2.9)7/22 (32)65/188 (35)Bicarbonate <21
mmol/L
††1.5 (0.5 to 4.6)4/29 (14)††§0/28 (0)37/191 (19)Urea >20 mg/dL
††1.1 (0.3 to 4.0)3/26 (12)††3.4 (0.4 to 26.2)1/24 (4)24/187 (13)Glucose >200 mg/dL
Platelet count:
††4.4 (1.0 to 19.2)2/41 (5)††4.7 (1.1 to 20.2)2/42 (5)40/207 (19)<150 000/μL
ReferenceReference34/41 (83)ReferenceReference36/42 (86)154/207 (74)150 000-450 000/μL
††0.6 (0.2 to 1.7)5/41 (12)††0.8 (0.2 to 2.5)4/42 (9)13/207 (6)>450 000/μL
CRT=capillary refill time.
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Table 3 (continued)
Age matched controls (n=265)Random controls (n=265)
Cases
(n=265)—No
(%)Predictor
Odds ratio (95% CI)*
No (%)
Odds ratio (95% CI)*
No (%)
Multivariable
model
Univariable
analysis
Multivariable
model
Univariable
analysis
*Random control results adjusted for site, age matched control results adjusted for site and age, using conditional logistic regression; for non-linear continuous
predictor variables, effect reported as parameter estimates (95% CI) for linear, quadratic, and cubic terms.
†Not identified as significant in univariable analyses or in initial multivariable models.
‡Not identified as significant in final model.
§Estimate and CI not calculated owing to non-prevalence in controls.
¶Not included in modelling process owing to prevalence in cases or controls ≤2%.
**Heart rate term for final multivariable model includes adjustment for age (random control model odds ratio 0.8 (95% CI 0.7 to 0.9); age matched control model
odds ratio 1.4 (95% CI 1.0 to 1.9)).
††Owing to reduced number of laboratory and radiographic investigations done in control groups, laboratory and radiographic investigation predictor variables
were not included in multivariable analysis.
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Table 4| Emergency department management and outcome of children who developed severe outcomes with pH1N1 infection. Values are
numbers (percentages) unless stated otherwise
Total (n=321)WILIE group (n=56)Cases (n=265)
Emergency department management
286 (89)50 (89)236 (89)Admitted to hospital at initial presentation
208 (65)37 (66)171 (65)Admitted to ICU at initial presentation
73 (23)20 (36)53 (20)Intubated
267 (83)48 (86)219 (83)Oxygen
46 (14)7 (13)39 (15)Non-invasive ventilation*
90 (28)22 (39)68 (26)Invasive ventilation†
204 (64)36 (64)168 (63)Intravenous fluid bolus
45 (14)6 (11)39 (15)Inotropic support
203 (63)27 (48)176 (66)Antibiotic treatment
130 (40)15 (27)115 (43)Antiviral treatment
Subsequent management in hospital
151/317 (48)21 (38)130/261 (50)Non-invasive ventilation
2.0 (0.7-3.6)1.1 (0.8-2.0)2.0 (0.7-3.8)Median (IQR) duration of non-invasive ventilation
(days)‡
183/317 (58)36 (64)147/261 (56)Invasive ventilation
6.1 (2.9-12.3)5.8 (2.3-10.8)6.4 (3-12.7)Median (IQR) duration of invasive ventilation
(days)§
17 (5)1 (2)16 (6)Extracorporeal membrane oxygenation
119/319 (37)16 (29)103/263 (39)Inotropic support
3.0 (1.5-6.0)3.3 (2.2-7.8)2.8 (1.4-6.0)Median (IQR) duration of inotropic support (days)¶
272/316 (86)45 (80)227/260 (87)Antibiotic treatment
6.0 (3.0-10.0)7.5 (3.5-10.0)6.0 (3.0-10.0)Median (IQR) duration of antibiotic treatment
(days)**
268/315 (85)47 (84)221/259 (85)Antiviral treatment
5 (5.0-5.5)5.0 (5.0-7.0)5.0 (5.0-5.5)Median (IQR) duration of antiviral treatment
(days)††
11/314 (4)4 (7)7/258 (3)Immunoglobulin treatment‡‡
161/316 (51)33 (59)128/260 (49)Steroid treatment‡‡
Outcome
90/319 (28)13/55 (24)77/264 (29)Subsequent pneumonia after admission
40/316 (13)2/53 (4)38/263 (14)Acute respiratory distress syndrome§§
82/319 (26)15 (27)67/263 (25)Secondary bacterial infection
24/316 (8)2/53 (4)22/263 (8)Acute kidney injury/renal insufficiency
12/315 (4)1/53 (2)11/262 (4)Myocarditis
6.0 (2.5-11.5)7 (1-10)6 (3-12)Median (IQR) ICU length of stay (days)
9.2 (4.7-17.7)11 (4-16)9 (5-18)Median (IQR) hospital length of stay (days)
34 (11)7(13)27 (10)Died
ICU=intensive care unit; IQR=interquartile range; WILIE=severe H1N1 without influenza-like illness in ED.
*Positive pressure ventilatory support not delivered via endotrachial tube, laryngeal mask airway (LMA), or surgical airway (that is, continuous positive airway
pressure).
†Ventilatory support delivered via endotrachial tube, LMA, or surgical airway.
‡Data available for 76 (50%) cases and WILIE patients.
§Data available for 96 (53%) cases and WILIE patients.
¶Data available for 61 (51%) cases and WILIE patients.
**Data available for 260 (96%) cases and WILIE patients.
††Data available for 248 (96%) cases and WILIE patients.
‡‡Treatment started either in emergency department or subsequently.
§§Defined as acute onset illness with PaO2/FIO2<200 (if PaO2 in mm Hg) or <26.6 (if PaO2 in kPa), bilateral diffuse chest radiograph opacities, absence of left sided
heart failure or elevated left atrial pressure, and invasive or non-invasive ventilation for >12 hours.
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Table 5| Emergency department management and outcome in children who survived and died from severe pH1N1 infection. Values are
numbers (percentages)
P valueAlive (n=287)Died (n=32)
Emergency department management
0.6963 (22)8 (25)Intubated
0.07242 (84)23 (72)Oxygen
0.7442 (15)4 (13)Non-invasive ventilation*
0.7380 (28)8 (25)Invasive ventilation†
0.10186 (65)16 (50)Fluid bolus
0.0435 (12)8 (25)Inotropic support
0.19186 (65)17 (53)Antibiotic treatment
0.02123 (43)7 (22)Antiviral treatment
Subsequent management in hospital
0.53135/285 (47)16/30 (53)Non-invasive ventilation
0.18160/283 (57)22 (69)Invasive ventilation
<0.00110 (3)7 (22)Extracorporeal membrane oxygenation
0.00298/285 (34)20 (63)Inotropic support
0.30247/283 (87)25/31 (81)Antibiotic treatment
0.83241/281 (85)27 (84)Antiviral treatment
0.068/280 (3)3 (9)Immunoglobulin treatment‡
0.55143/282 (51)18 (56)Steroid treatment‡
Outcome
0.0476/285 (27)14 (44)Subsequent pneumonia after admission
<0.00130/283 (11)10/31 (32)Acute respiratory distress syndrome§
0.0168/285 (24)14 (44)Secondary bacterial infection
<0.00116/283 (6)8/31 (26)Acute kidney injury/renal insufficiency
<0.0017/282 (2)5/31 (16)Myocarditis
Data exclude two participants who arrived in emergency department in non-survivable cardiac arrest.
*Positive pressure ventilatory support not delivered via an endotrachial tube, laryngeal mask airway (LMA), or surgical airway (that is, continuous positive airway
pressure).
†Ventilatory support delivered via endotrachial tube, LMA, or surgical airway.
‡Treatment started either in emergency department or subsequently.
§Defined as acute onset illness with PaO2/FIO2<200 (if PaO2 in mm Hg) or <26.6 (if PaO2 in kPa), bilateral diffuse chest radiograph opacities, absence of left sided
heart failure or elevated left atrial pressure, and invasive or non-invasive ventilation for >12 hours.
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